

Nabila Dahodwala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8932850/publications.pdf>

Version: 2024-02-01

70
papers

29,799
citations

159585

30
h-index

91884

69
g-index

71
all docs

71
docs citations

71
times ranked

49250
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 421-436.	2.8	11
2	Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare Population. <i>Movement Disorders</i> , 2021, 36, 133-142.	3.9	23
3	Patterns and predictors of referrals to allied health services for individuals with Parkinson's disease: A Parkinson's foundation (PF) QII study. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 115-122.	2.2	10
4	Current Knowledge on the Evolution of Care Partner Burden, Needs, and Coping in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 510-520.	1.5	11
5	Whole Clinic Research Enrollment in Parkinson's Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 757-765.	2.8	5
6	Low Sustainment of High-Dose Oral Medication Regimens for Advanced Parkinson's Disease in Medicare Beneficiaries. <i>Journal of Parkinson's Disease</i> , 2021, 11, 675-684.	2.8	4
7	Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 737-745.	2.8	5
8	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , 2020, 19, 71-80.	10.2	94
9	Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2020, 61, 508-511.	2.2	47
10	Current and projected future economic burden of Parkinson's disease in the U.S.. <i>Npj Parkinson's Disease</i> , 2020, 6, 15.	5.3	265
11	Overcoming Barriers to Parkinson Disease Trial Participation: Increasing Diversity and Novel Designs for Recruitment and Retention. <i>Neurotherapeutics</i> , 2020, 17, 1724-1735.	4.4	27
12	Tau pathology associates with in vivo cortical thinning in Lewy body disorders. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2342-2355.	3.7	20
13	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1816-1830.	3.7	23
14	Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience. <i>Journal of Parkinson's Disease</i> , 2020, 10, 665-675.	2.8	25
15	Use of a medication-based algorithm to identify advanced Parkinson's disease in administrative claims data: Associations with claims-based indicators of disease severity. <i>Clinical Parkinsonism & Related Disorders</i> , 2020, 3, 100046.	0.9	7
16	Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?. <i>Movement Disorders</i> , 2020, 35, 1618-1625.	3.9	31
17	Integrated Care in Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>Movement Disorders</i> , 2020, 35, 1509-1531.	3.9	71
18	Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor and Other Hyperkinetic Movements, 2020, 10, 29.	2.0	35

#	ARTICLE	IF	CITATIONS
19	Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 440-445.	1.5	15
20	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019, 62, 201-209.	2.2	15
21	Quality of education impacts late-life cognition. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 855-862.	2.7	28
22	Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2019, 69, 119-124.	2.2	26
23	Pharmacological treatment of apathy in Lewy body disorders: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 14-24.	2.2	15
24	Continuous EEG is associated with favorable hospitalization outcomes for critically ill patients. <i>Neurology</i> , 2019, 92, e9-e18.	1.1	91
25	Sex disparities in health and health care utilization after Parkinson diagnosis: Rethinking PD associated disability. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 45-50.	2.2	15
26	Impact of Cost-sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study. <i>Health Services Research</i> , 2018, 53, 2735-2757.	2.0	22
27	<i>APOE</i> , thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 289-297.	3.9	35
28	Sex disparities in access to caregiving in Parkinson disease. <i>Neurology</i> , 2018, 90, e48-e54.	1.1	58
29	Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2018, 17, 939-953.	10.2	1,573
30	Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. <i>Npj Parkinson's Disease</i> , 2018, 4, 19.	5.3	110
31	Improved availability and quality of care with epilepsy nurse practitioners. <i>Neurology: Clinical Practice</i> , 2017, 7, 109-117.	1.6	19
32	Parkinsonian signs are a risk factor for falls. <i>Gait and Posture</i> , 2017, 55, 1-5.	1.4	11
33	Longitudinal decline in speech production in Parkinson's disease spectrum disorders. <i>Brain and Language</i> , 2017, 171, 42-51.	1.6	43
34	Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis. <i>Journal of Parkinson's Disease</i> , 2017, 7, 385-395.	2.8	21
35	Utilization of rehabilitation therapy services in Parkinson disease in the United States. <i>Neurology</i> , 2017, 89, 1162-1169.	1.1	53
36	Postdiagnosis neurological care for patients with psychogenic nonepileptic spells (PNES). <i>Epilepsy and Behavior</i> , 2017, 74, 64-68.	1.7	3

#	ARTICLE	IF	CITATIONS
37	Statins and Cognition in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 661-667.	2.8	13
38	Prevalence and Correlates of Anti-Parkinson Drug Use in a Nationally Representative Sample. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 335-341.	1.5	22
39	The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 21-26.	2.2	42
40	Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire. <i>Movement Disorders</i> , 2016, 31, 126-134.	3.9	20
41	Sex Differences in the Clinical Progression of Parkinson's Disease. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2016, 45, 749-756.	0.5	31
42	Computerized assessment of goal-directed behavior in Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 1015-1025.	1.3	5
43	Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 584.	7.4	192
44	Analysis of the treatment of neuromyelitis optica. <i>Journal of the Neurological Sciences</i> , 2015, 351, 31-35.	0.6	86
45	Longitudinal study of normal cognition in Parkinson disease. <i>Neurology</i> , 2015, 85, 1276-1282.	1.1	197
46	Caregiver report of apathy predicts dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 992-995.	2.2	29
47	Health literacy and medication awareness in outpatient neurology. <i>Neurology: Clinical Practice</i> , 2014, 4, 71-81.	1.6	10
48	Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale scores in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1809-1815.	3.9	86
49	Sex differences in Parkinson's disease and other movement disorders. <i>Experimental Neurology</i> , 2014, 259, 44-56.	4.1	144
50	Surface EMG activity during REM sleep in Parkinson's disease correlates with disease severity. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 766-771.	2.2	36
51	Knowledge and Attitudes About Parkinson's Disease Among a Diverse Group of Older Adults. <i>Journal of Cross-Cultural Gerontology</i> , 2014, 29, 339-352.	1.0	34
52	Utilization of care among drug resistant epilepsy patients with symptoms of anxiety and depression. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2014, 23, 196-200.	2.0	23
53	Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 859-863.	2.2	40
54	Daytime Sleepiness is Associated with Falls in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2013, 3, 387-391.	2.8	14

#	ARTICLE	IF	CITATIONS
55	Questionnaire-based diagnosis of REM sleep behavior disorder in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1146-1149.	3.9	52
56	What is known about racial disparities in Parkinson's disease diagnosis and treatment?. <i>Neurodegenerative Disease Management</i> , 2013, 3, 485-487.	2.2	2
57	Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2129-2143.	13.7	1,013
58	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2197-2223.	13.7	7,061
59	Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2095-2128.	13.7	11,038
60	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2163-2196.	13.7	6,376
61	Screening questionnaires for parkinsonism: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 216-224.	2.2	17
62	Validation of an Instrument to Measure Older Adults' Expectations Regarding Movement (ERM). <i>PLoS ONE</i> , 2012, 7, e43854.	2.5	3
63	Can a Screening Questionnaire Accurately Identify Mild Parkinsonian Signs. <i>Neuroepidemiology</i> , 2012, 39, 171-175.	2.3	6
64	Genetic influences on cognitive decline in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 512-518.	3.9	127
65	Delayed Parkinson's Disease Diagnosis among African-Americans: The Role of Reporting of Disability. <i>Neuroepidemiology</i> , 2011, 36, 150-154.	2.3	37
66	Reply: Racial differences in the diagnosis of Parkinson's disease-Not just a North American issue. <i>Movement Disorders</i> , 2010, 25, 2256-2257.	3.9	0
67	Treatment disparities in Parkinson's disease. <i>Annals of Neurology</i> , 2009, 66, 142-145.	5.3	63
68	Racial differences in the diagnosis of Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1200-1205.	3.9	88
69	Neurology education and global health: My rotation in Botswana. <i>Neurology</i> , 2007, 68, E15-E16.	1.1	10
70	Interest in predictive testing for Parkinson's disease: Impact of neuroprotective therapy. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 495-499.	2.2	15